Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP475893.RAlNDsjcAxaInRiOY1m5Ttu_t4PPKJVtPNM2IwhY-73yM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP475893.RAlNDsjcAxaInRiOY1m5Ttu_t4PPKJVtPNM2IwhY-73yM130_assertion type Assertion NP475893.RAlNDsjcAxaInRiOY1m5Ttu_t4PPKJVtPNM2IwhY-73yM130_head.
- NP475893.RAlNDsjcAxaInRiOY1m5Ttu_t4PPKJVtPNM2IwhY-73yM130_assertion description "[The concentration of thrombin-activatable fibrinolysis inhibitor was particularly higher in patients with small cell carcinoma compared to those with adenocarcinoma or squamous cell carcinoma, and in cancer patients that responded to chemotherapy compared to non-responders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP475893.RAlNDsjcAxaInRiOY1m5Ttu_t4PPKJVtPNM2IwhY-73yM130_provenance.
- NP475893.RAlNDsjcAxaInRiOY1m5Ttu_t4PPKJVtPNM2IwhY-73yM130_assertion evidence source_evidence_literature NP475893.RAlNDsjcAxaInRiOY1m5Ttu_t4PPKJVtPNM2IwhY-73yM130_provenance.
- NP475893.RAlNDsjcAxaInRiOY1m5Ttu_t4PPKJVtPNM2IwhY-73yM130_assertion SIO_000772 15224354 NP475893.RAlNDsjcAxaInRiOY1m5Ttu_t4PPKJVtPNM2IwhY-73yM130_provenance.
- NP475893.RAlNDsjcAxaInRiOY1m5Ttu_t4PPKJVtPNM2IwhY-73yM130_assertion wasDerivedFrom befree-20140225 NP475893.RAlNDsjcAxaInRiOY1m5Ttu_t4PPKJVtPNM2IwhY-73yM130_provenance.
- NP475893.RAlNDsjcAxaInRiOY1m5Ttu_t4PPKJVtPNM2IwhY-73yM130_assertion wasGeneratedBy ECO_0000203 NP475893.RAlNDsjcAxaInRiOY1m5Ttu_t4PPKJVtPNM2IwhY-73yM130_provenance.